IL6 and COVID-19: Taken together, endothelial dysfunction (elevated vWF level), with the release of fibrinolysis inhibitor PAI-1, and hyperimmune response (increased ESR, CRP, ferritin, and IL-6) with younger (higher H-IPF) activated platelets seem to be significant contributors to thrombogenesis in COVID-19.